Alexander Drilon, MD

Dr. Alexander Drilon presents an update from the Phase 1/2 ALKOVE-1 study, investigating the efficacy and safety of NVL-655, a selective ALK inhibitor, in patients with ALK-positive solid tumors, highlighting durable responses in heavily pre-treated populations, including those with compound ALK resistance mutations and central nervous system involvement.

Alexander Drilon, MD, discusses efficacy findings from the TRUST-I and TRUST-II trials in patients with ROS1+ non–small cell lung cancer.

Alexander Drilon, MD, discusses the potential benefit of taletrectinib in patients with ROS1-positive non–small cell lung cancer.

Alexander Drilon, MD, discusses the significance of the FDA approval of selpercatinib in RET fusion–positive solid tumors.

Alexander Drilon, MD, discusses prior therapy and performance status outcomes for larotrectinib in patients with non-CNS TRK fusion cancer that were presented at the European Society of Medical Oncology 2021 annual meeting.

Alexander Drilon, MD, discusses the efficacy and safety data of larotrectinib in patients with tropomyosin receptor kinase (TRK) fusion-positive lung cancer that was presented at the World Cancer Lung Conference 2021 annual meeting.

Alexander Drilon, MD, discusses the utility of brigatinib in ALK-positive non–small cell lung cancer.

Alexander Drilon, MD, discusses the potential utility of immunotherapy in ALK fusion-positive non–small cell lung cancer.

Alexander Drilon, MD, discusses the safety profile of brigatinib in ALK-positive non­–small cell lung cancer.

Alexander Drilon, MD, discusses what factors he considers when selecting treatment for patients with ALK fusion-positive non–small cell lung cancer.

Alexander Drilon, MD, discusses performing comprehensive sequencing in lung cancer.

Alexander Drilon, MD, research director, Memorial Sloan Kettering Cancer Center, discusses the results of LIBRETTO-001, a phase I/II trial of RET inhibitor, selpercatinib in patients with RET fusion non-small cell lung cancers.

Alexander Drilon, MD, medical oncologist, clinical director, Early Drug Development Service, Memorial Sloan Kettering Cancer Center, discusses emerging biomarkers in non–small cell lung cancer (NSCLC).

Alexander Drilon, MD, medical oncologist, clinical director, Early Drug Development Service, Memorial Sloan Kettering Cancer Center, discusses the FDA approval larotrectinib in NTRK-positive cancers.

Alexander Drilon, MD, medical oncologist, clinical director, Early Drug Development Service, Memorial Sloan Kettering Cancer Center, discusses findings from the phase I LIBRETTO-001 study exploring the highly selective RET inhibitor LOXO-292 in patients with RET-altered solid tumors.

Alexander Drilon, MD, clinical director, Early Drug Development Service, Memorial Sloan Kettering Cancer Center, discusses targeted agents for patients with ROS1-rearranged lung cancer.

Alexander Drilon, MD, medical oncologist, Memorial Sloan Kettering Cancer Center, discusses central nervous system penetration in the treatment of non-small cell lung cancer.

Alexander Drilon, MD, medical oncologist, Memorial Sloan Kettering Cancer Center, discusses the role of MET in patients with lung cancer.

Alexander Drilon, MD, medical oncologist, Memorial Sloan Kettering Cancer Center, discusses a study exploring entrectinib in patients with ROS1-positive, advanced or metastatic non-small cell lung cancer (NSCLC) during an interview at the IASLC 18th World Conference on Lung Cancer in Yokohama, Japan.

Alexander Drilon, MD, medical oncologist, Memorial Sloan Kettering Cancer Center, discusses immunotherapy in patients with lung cancer.

Alexander Drilon, MD, medical oncologist, Memorial Sloan Kettering Cancer Center, discusses NTRK rearrangement in patients with lung cancer.

Alexander Drilon, MD, medical oncologist, Memorial Sloan Kettering Cancer Center, discusses RET rearrangements for patients with non–small cell lung cancer (NSCLC).

Alexander Drilon, MD, medical oncologist, Memorial Sloan Kettering Cancer Center, discusses two studies investigating entrectinib in patients with advanced solid tumors.